Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

seed pharma limited - alfentanil hydrochloride 0.5435 mg/ml equivalent to 0.5 mg/ml alfentanil - solution for injection - 0.5 mg/ml - active: alfentanil hydrochloride 0.5435 mg/ml equivalent to 0.5 mg/ml alfentanil excipient: sodium chloride water for injection - rapifen is indicated for use as: " an opioid analgesic in general or regional anaesthesia for both short (bolus injections) and long (bolus, supplemented by increments or by continuous infusion) surgical procedures. " an anaesthetic induction agent. due to its rapid and short lasting action, rapifen is particularly suited as an opioid analgesic for short procedures and outpatient surgery. it is also useful as an analgesic supplement for procedures of medium and long duration, since periods of very painful stimuli can easily be overcome by small increments of rapifen or by adapting its infusion rate.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tiotropium bromide monohydrate 22.5ug equivalent 18 µg tiotropium - powder filled inhalation capsule - 18 mcg - active: tiotropium bromide monohydrate 22.5ug equivalent 18 µg tiotropium excipient: gelatin lactose monohydrate - spiriva is indicated for the long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib;   - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide red magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 33.4mg equivalent to 25 mg sunitinib;   - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to 25 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 66.8mg equivalent to 50 mg sunitinib;   - capsule - 50 mg - active: sunitinib malate 66.8mg equivalent to 50 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lymecycline 408mg equivalent to 300 mg tetracycline base - capsule - 300 mg - active: lymecycline 408mg equivalent to 300 mg tetracycline base excipient: erythrosine gelatin hydrated silica indigo carmine magnesium stearate quinoline yellow sulfur dioxide titanium dioxide - tetralysal is a broad spectrum antibiotic and is recommended for the treatment of all infections caused by tetracycline sensitive organisms and may be utilised in all conditions where tetracycline therapy is indicated. in common with other tetracyclines it is indicated in penicillin-sensitive patients for the treatment of staphylococcal infections. typical infections include: ear, nose and throat infections; acute and chronic bronchitis (including prophylaxis); infections of the gastrointestinal and urinary tracts; non-gonococcal urethritis of chlamydial origin; and other chlamydial infections such as trachoma; acne; rickettsial fevers; soft tissue infections.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clindamycin hydrochloride 162.87mg equivalent to clindamycin 150 mg;  ;   - capsule - 150 mg - active: clindamycin hydrochloride 162.87mg equivalent to clindamycin 150 mg     excipient: gelatin lactose monohydrate magnesium stearate maize starch opacode black s-1-277002 purified talc titanium dioxide - clindamycin hydrochloride has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: · upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. · lower respiratory infections including bronchitis, pneumonia, emphysema and lung abscess. · skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. for specific skin and soft tissue infections like erysipelas and paronychia (panaritium), it would seem logical that these conditions would respond very well to clindamycin therapy. · bone and joint infections including osteomyelitis and septic arthritis. · pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. in cases of cervicitis due to chlamydia trachomatis, mono therapy with clindamycin has been shown to be effective in eradicating the organism. · intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. · septicemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations. · dental infections such as periodontal abscess and periodontitis. · as an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant plasmodium falciparum infection.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - tropisetron hydrochloride 1.13 mg/ml equivalent to tropisetron 1 mg/ml - solution for injection - 1 mg/ml - active: tropisetron hydrochloride 1.13 mg/ml equivalent to tropisetron 1 mg/ml excipient: acetic acid sodium acetate trihydrate sodium chloride water for injection - prevention of nausea and vomiting induced by cytoxic therapy (5mg/5ml ampoule only).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - pazopanib hydrochloride 216.7mg equivalent to 200 mg pazopanib base;  ;   - film coated tablet - 200 mg - active: pazopanib hydrochloride 216.7mg equivalent to 200 mg pazopanib base     excipient: magnesium stearate microcrystalline cellulose opadry pink ys-1-14762-a povidone sodium starch glycolate - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base;  ;   - film coated tablet - 400 mg - active: pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base     excipient: magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g povidone sodium starch glycolate - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).